---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000049"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:29:12.600393+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q1 rev $237.5M (+20.5%); raises FY 2026 guidance, authorizes $100M buyback

## Summary
- Q1 net revenue $237.5M (+20.5% YoY); GAAP diluted EPS $1.28; adj non-GAAP diluted EPS $2.05.
- Cortrophin Gel rev $75.1M (+42.1%); ILUVIEN rev $19.3M (+19.5%); Generics rev $105.4M (+6.8%).
- Raised FY 2026 guidance: rev $1,080M-$1,140M; adj EBITDA $285M-$300M; adj diluted EPS $9.19-$9.69.
- Board authorized $100M share repurchase program through May 2029; cash from operations $58.4M in Q1.
- Harmony Agreement contributed $15M upfront + $6.5M royalties; $10M milestone expected in Q2/Q3 2026.

## SEC filing metadata
- accession: 0001023024-26-000049
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/0001023024-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/ani-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000049
- JSON: https://secwatch.observer/filing/0001023024-26-000049.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000049.txt

## Source-grounded claims
- claim_id: d0ca0b645a96ad2dc7582945b920df4896825b64
  claim: ANI PHARMACEUTICALS INC reported first quarter ended March 31, 2026 results: revenue $237.5 million, net income $29.5 million, EPS $1.28. Guidance raised.
  evidence_excerpt: ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance • Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year • Purified Cortrophin ® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year • Quarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-year • Diluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/0001023024-26-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.